EGFR and non-small cell lung carcinoma: Relatedly, some studies have reported encouraging results for the treatment of positive EGFR-mutant NSCLC patients with BM with EGFR-TKIs alone, including PFS durations of 6.6 to 15.2 months and OS durations of 12.9 to 18.9 months [11–15].